WO2012016646A9 - Quetiapin-tabletten - Google Patents

Quetiapin-tabletten Download PDF

Info

Publication number
WO2012016646A9
WO2012016646A9 PCT/EP2011/003689 EP2011003689W WO2012016646A9 WO 2012016646 A9 WO2012016646 A9 WO 2012016646A9 EP 2011003689 W EP2011003689 W EP 2011003689W WO 2012016646 A9 WO2012016646 A9 WO 2012016646A9
Authority
WO
WIPO (PCT)
Prior art keywords
quetiapine
quetiapine tablets
tablets
matrix
tablet
Prior art date
Application number
PCT/EP2011/003689
Other languages
English (en)
French (fr)
Other versions
WO2012016646A1 (de
Inventor
Klaus Neuer
Daniel Rast
Jörg BESSER
Original Assignee
Acino Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acino Pharma Ag filed Critical Acino Pharma Ag
Publication of WO2012016646A1 publication Critical patent/WO2012016646A1/de
Publication of WO2012016646A9 publication Critical patent/WO2012016646A9/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft eine Tablette mit einer Matrix aus einem Gemisch von mindestens zwei Zuckeralkoholen, wobei die Matrix als Wirkstoff Quetiapin oder ein Salz davon enthält.
PCT/EP2011/003689 2010-08-05 2011-07-22 Quetiapin-tabletten WO2012016646A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010033527.4 2010-08-05
DE102010033527A DE102010033527A1 (de) 2010-08-05 2010-08-05 Quetiapin-Tabletten

Publications (2)

Publication Number Publication Date
WO2012016646A1 WO2012016646A1 (de) 2012-02-09
WO2012016646A9 true WO2012016646A9 (de) 2012-09-07

Family

ID=44630087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/003689 WO2012016646A1 (de) 2010-08-05 2011-07-22 Quetiapin-tabletten

Country Status (2)

Country Link
DE (1) DE102010033527A1 (de)
WO (1) WO2012016646A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
SG11202113266YA (en) 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US5075291A (en) 1989-11-22 1991-12-24 Ici Americas Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
US20050003001A1 (en) * 2001-11-07 2005-01-06 Hisami Yamaguchi Method for improving dissolution of poorly dispersible medicaments
US20060013876A1 (en) 2002-06-26 2006-01-19 Lohray Braj B Novel floating dosage form
JP2007509155A (ja) 2003-10-21 2007-04-12 アルファーマ インコーポレイテッド クエチアピンを含有する薬剤
JP2009500317A (ja) 2005-06-29 2009-01-08 パナセア バイオテック リミテッド 放出特性改良医薬組成物およびその製造方法
EP1976487A2 (de) * 2006-01-25 2008-10-08 Astron Research Limited Dosierung mit verzögerter freigabe von phenothiazin-derivaten mit kanalisierern
AU2007211101B2 (en) 2006-01-27 2013-05-02 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
MX2008014059A (es) 2006-05-09 2008-11-14 Mallinckrodt Inc Formas de dosificacion solida de liberacion modificada en el orden de cero.
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette

Also Published As

Publication number Publication date
WO2012016646A1 (de) 2012-02-09
DE102010033527A1 (de) 2012-02-09

Similar Documents

Publication Publication Date Title
IL259296B (en) Sodium salt of (r1,s2,r5)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
IL258908A (en) Bismam thiols as disinfectants for use in agriculture, industry and other uses
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
EP2522653A4 (de) Biguanidderivat, herstellungsverfahren dafür und pharmazeutische zusammensetzung mit dem biguanidderivat als wirkstoff
WO2011012816A3 (fr) Formulation pharmaceutique
ZA201007679B (en) Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup,processes for their preparation and their use as pharmaceuticals
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
WO2011144674A3 (en) PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2009135593A3 (de) Feste arzneimittelformulierung mit verzögerter freisetzung
CA2863376A1 (en) Gastroretentive tablets
EP2630956B8 (de) Retardierte pellets mit tacrolimus als wirkstoff
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
ZA201404035B (en) Microcapsule containing fungicidal active ingredient
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2011120903A3 (en) A fast dissolving pharmaceutical composition
WO2014044342A8 (de) Magnesiumhydroxidcarbonat als trägermaterial in wirkstoffhaltigen zubereitungen
WO2010119102A3 (de) Pharmaceutische zusammensetzung enthaltend protonenpumpenhemmer zur behandlung von dermatologischen autoimmunerkrankungen
WO2012016646A9 (de) Quetiapin-tabletten
HK1152652A1 (en) Pharmaceutical solid preparation having active ingredients separated by boundary therein
WO2011097527A3 (en) Immunoprotection of therapeutic moieties using enhanced fc regions
WO2011156045A3 (en) Tablet formulation of ezatiostat
EP2864328B8 (de) Pharmazeutisch aktive verbindungen
EP2476420B8 (de) Pharmazeutische zusammensetzung mit antimikrobieller und schnell heilender wirkung zur externen verabreichung sowie herstellungsverfahren dafür

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11743192

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 11743192

Country of ref document: EP

Kind code of ref document: A1